Is Methylphenidate Like Cocaine?: Studies on Their Pharmacokinetics and Distribution in the Human Brain

Archives of General Psychiatry

Volumn 52, Issue 6, 1995, Pages 456-463

  Volkow, Nora D ^a,b   Ding, Yu Shin ^a   Fowler, Joanna S ^a   Wang, Gene Jack ^a   Logan, Jean ^a   Gatley, John S ^a   Dewey, Stephen ^a   Ashby, Charles ^a   Liebermann, Jeffrey ^c   Hitzemann, Robert ^b   Wolf, Alfred P ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; METHYLPHENIDATE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ABUSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISTRIBUTION; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY;

ADULT; ANIMAL; BRAIN; CARBON RADIOISOTOPES; CEREBELLUM; COCAINE; COMPARATIVE STUDY; CORPUS STRIATUM; HALF-LIFE; HUMAN; MALE; METHYLPHENIDATE; MIDDLE AGE; PAPIO; SELF MEDICATION; SUBSTANCE-RELATED DISORDERS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029039269     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1995.03950180042006     Document Type: Article

References (54)

1. Fischman MW, Schuster CR. Cocaine self administration in humans. Fed Proc. 1988;41: 241–246.
2. Johanson CE, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol Rev. 1989;41: 3–52.
3. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science. 1988;242: 715–723.
4. Wilens TE, Biederman J. The stimulants. Pediatr Psychopharmacol. 1992;15: 191–222.
5. Barkley RA. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry. 1977;8: 137–165.
6. Safer DJ, Krager JM. Effect of a media blitz and a threatened lawsuit on stimulant treatment. JAMA. 1992;268: 1004–1007.
7. Meyer JS, Sakai F, Karacan I, Derman S, Yamamoto M. Sleep apnea, narcolepsy, and dreaming: regional cerebral hemodynamics. Ann Neurol. 1980;7: 479–485.
8. Kaufman MW, Cassem NH, Murray GB, Jenike M. Use of psychostimulants in medically ill patients with neurological disease and major depression. Can J Psychiatry. 1984;29: 46–49.
9. Pollack MH, Brotman AW, Rosenbaum JF. Cocaine abuse and treatment. Compr Psychiatry. 1989;30: 31–44.
10. Khantzian EJ, Gawin FH, Riordan C, Kleber HD. Methylphenidate treatment of cocaine dependence: a preliminary report. J Subst Abuse Treat. 1984;1: 107–112.
11. Chiarello RJ, Cole JO. The use of psychostimulant in general psychiatry. Arch Gen Psychiatry. 1987;44: 266–295.
12. Parran TV, Jasinski DR. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med. 1991;151: 781–783.
13. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237: 1219–1223.
14. Bergman J, Madras B, Johnson SE, Spealman RD. Effects of cocaine and related drugs in nonhuman primates, III: self administration by squirrel monkeys. J Pharmacol Exp Ther. 1989;251: 150–155.
15. Johanson CE, Shuster CR. A choice procedure for drug reinforcers: cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exper Ther. 1975;193: 676–688.
16. Wilson MC, Hitomi M, Schuster CR. Psychomotor self administration as a function of dosage per injection in the rhesus monkey. Psychopharmacology. 1971;22: 271–281.
17. Jeffe RB, Koschmann EB. Intravenous drug abuse, pulmonary cardiac and vascular complications. AJR Am J Roentgenol, 1970;109: 107–120.
18. Lewman LV. Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol. 1972;3: 67–70.
19. Oldendorf WH. Some relationships between addiction and drug delivery to the brain. In: Frankenheim J, Brown RM, eds. Bioavailability of Drugs to the Brain and the Blood Brain Barrier. Rockville, MD: National Institute on Drug Abuse; 1992: 13–25. Research Monograph 120.
20. Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effects of dose and infusion duration. J Exp Anal Behav. 1973;20: 119–129.
21. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Logan J, Bendriem B, Gatley SJ, Christman D. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse. 1989;4: 371–377.
22. Ding Y-S, Fowler JS, Volkow ND, Gatley SJ, Dewey SL, Martin T, Jenkins D, Alexoff D, Salata C, Wolf AP. Synthesis of [11C]dl-threo-methylphenidate: drug pharmacokinetics and binding to the presynaptic dopaminergic neuron. Synapse. 1994;18: 152–160.
23. Dewey SL, MacGregor RR, Brodie JD, Bendriem B, King PT, Volkow ND, Schlyer DJ, Fowler JS, Wolf AP, Gately SJ, Hitzemann R. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse. 1990;5: 213–223.
24. Bendriem B, Dewey SL, Schlyer DJ, Wolf AP, Volkow ND. Quantitation of the human basal ganglia with positron emission tomography: a phantom study of the effect of contrast and axial positioning. IEEE Trans Med Imaging. 1991;10: 216–222.
25. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewer SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR. Graphical analysis of reversible radioligand binding time-activity measurements applied to [N-11Cmethyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10: 740–747.
26. Logan J, Volkow ND, Fowler JS, Wang G-J, Dewey SL, MacGregor R, Schlyer D, Gatley S-J, Pappas N, King P, Hitzmann R, Vitkun S. Effects of blood flow on [11C]reclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab. 1994;14: 995–1010.
27. Cook CE, Jeffcoat AR, Perez-Reyes M. Pharmacokinetic studies of cocaine and phenylciclidine in man. In: Barnett G, Chiang CN, eds. Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Foster City, Calif: Biomedical publication; 1985: 48–74.
28. Unis AS, Dawson TM, Gehlert DR, Wamsley JK. Autoradiographic localization of [3H]-methylphenidate binding sites in rat brain. Eur J Pharmacol. 1985;113: 155–157.
29. Seeman P. Receptor Tables: Drug Dissociation for Neuroreceptors and Transporters. Toronto, Ontario: Sz Research; 1993;2.
30. Laduron PM. Criteria for receptor sites in binding studies. Biochem Pharmacol. 1984;33: 833–839.
31. Pristupa ZB, Wilson J, Hoffman B, Kish SJ, Niznik HB. Pharmacological heterogeneity of the cloned and native human dopamine transporter: dissociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1993;45: 125–135.
32. Benuck M, Lajtha A, Reith MEA. Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice. J Pharmacol Exp Ther. 1987;243: 144–149.
33. Kennerly PS, Ellington KR, Breese GR. J Pharmacol Exp Ther. 1984;231: 61–67.
34. Van Dyke C, Jatlow P, Barash PG, Byck R. Oral cocaine: plasma concentrations and central effects. Science. 1978;100: 211–213.
35. Javaid JI, Musa MN, Fischman M, Schuster CR, Davis JM. Kinetics of cocaine in humans after intravenous and intranasal administration. Biopharm Drug Dispos. 1983;4: 9–18.
36. Jeffcoat AR, Perez Reyes M, Hill JM, Sadler BM, Cook CE. Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting) or smoking. Drug Metab Dispos Biol Fate Chem. 1989;17: 153–159.
37. Srinivas NR, Hubbard JW, Quinn D, Korchinski ED, Midha K. Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15: 213–220.
38. Holmstedt B, Lindgren JE, River L. Cocaine in blood of coca chewers. J Ethnopharmacol. 1979;1: 69–78.
39. Javaid J, Fischman MW, Schuster CR, Dekirmenjian H, Davis JM. Cocaine plasma concentration: relation to physiological and subjective effects in humans. Science. 1978;201: 227–228.
40. Foltin RW, Fischman M. Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther. 1991;257: 247–261.
41. Wargin W, Kilts PC, Gualtieri CT, Ellington K, Mueller RA, Kraemer G, Breese GR. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther. 1983;226: 382–386.
42. Inaba T. Cocaine: pharmacokinetics and biotransformation in man. Can J Physiol Pharmacol. 1988;67: 1154–1157.
43. Hurd YL, Kehr J, Ungerstedt U. In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. J Neurochem. 1988;51: 1314–1316.
44. Nicolaysen LC, Pan HT, Justice JB. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res. 1988;456: 317–323.
45. Ambre JJ. Cocaine kinetics in humans. In: Redda KK, Walker CA, Barnett G, eds. Cocaine, Marijuana, Designer Drugs, Chemistry, Pharmacology and Behavior. Boca Raton, Fla: CRC Press Inc; 1989: 53–69.
46. Chiodo LA. Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology. Neurosci Biobehav Rev. 1988;12: 49–91.
47. Einhorn LC, Johansen PA, White FJ. Electrophysiological effects of cocaine in the mesoaccumbens system: studies in the ventral tegmental area. J Neurosci. 1988;8: 100–112.
48. Meiergerd SM, Patterson TA, Schenk JO. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem. 1993;61: 764–767.
49. Parsons LH, Schad CA, Justice JB Jr. Co-administration of the D2 antagonist pimozide inhibits up-regulation of dopamine release and uptake induced by repeated cocaine. J Neurochem. 1993;60: 376–379.
50. Memo M, Lovenberg W, Hanbauer I. Agonist-induced subsensitivity of adenylate cyclase coupled with a dopamine receptor in slices from rat corpus striatum. Proc Nati Acad Sci USA. 1982;79: 4456–4460.
51. Salmon E, Brooks DJ, Leenders KL, Turton DR, Hume SP, Cremer JE, Jones T, Frackowiak RSJ. A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab. 1990;10: 307–316.
52. Wong RDF, Yung B, Dannals RF, Shaya EK, Ravert HT, Chen CA, Chan B, Folio T, Scheffel U, Ricaurte GA, Neumeyer JL, Wagner H, Kuhar MJ. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35428. Synapse. 1993;15: 130–142.
53. Innis RB, Seybel JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, Gao Y, Neumeyer JL, Charney DS, Hoffer PB, Marek KL. Single-photon emission-computed tomography imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Nati Acad Sci USA. 1993;90: 11965–11969.
54. Spyraki C, Fibiger HC. Intravenous self-administration of nomifensine in rats: implications for abuse potential in humans. Science. 1981;212: 1167–1168.